These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 7552480)

  • 1. Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS.
    Burger D; Meenhorst P; Mulder J; Henrichs J; Frissen J; Kroon F; ten Napel C; Koks K; Bult A; Beijnen J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct; 10(2):163-8. PubMed ID: 7552480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifabutin absorption in the gut unaltered by concomitant administration of didanosine in AIDS patients.
    Li RC; Narang PK; Sahai J; Cameron W; Bianchine JR
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1566-70. PubMed ID: 9210686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.
    Hartman NR; Yarchoan R; Pluda JM; Thomas RV; Wyvill KM; Flora KP; Broder S; Johns DG
    Clin Pharmacol Ther; 1991 Sep; 50(3):278-85. PubMed ID: 1914362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation.
    Knupp CA; Milbrath R; Barbhaiya RH
    J Clin Pharmacol; 1993 Jun; 33(6):568-73. PubMed ID: 8366182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.
    Knupp CA; Shyu WC; Dolin R; Valentine FT; McLaren C; Martin RR; Pittman KA; Barbhaiya RH
    Clin Pharmacol Ther; 1991 May; 49(5):523-35. PubMed ID: 1903100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus.
    Knupp CA; Brater DC; Relue J; Barbhaiya RH
    J Clin Pharmacol; 1993 Oct; 33(10):912-7. PubMed ID: 8227460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.
    Barry M; Howe JL; Ormesher S; Back DJ; Breckenridge AM; Bergin C; Mulcahy F; Beeching N; Nye F
    Br J Clin Pharmacol; 1994 May; 37(5):421-6. PubMed ID: 8054247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of spontaneous gastric hypoacidity on the pharmacokinetics of zidovudine and didanosine.
    Shelton MJ; Adams JM; Hewitt RG; Steinwandel C; DeRemer M; Cousins S; Morse GD
    Pharmacotherapy; 1997; 17(3):438-44. PubMed ID: 9165548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.
    De Forni D; Stevens MR; Lori F
    Br J Pharmacol; 2010 Oct; 161(4):830-43. PubMed ID: 20860662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
    Lambert JS; Seidlin M; Reichman RC; Plank CS; Laverty M; Morse GD; Knupp C; McLaren C; Pettinelli C; Valentine FT
    N Engl J Med; 1990 May; 322(19):1333-40. PubMed ID: 2139173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnitude and duration of elevated gastric pH in patients infected with human immunodeficiency virus after administration of chewable, dispersible, buffered didanosine tablets.
    DePestel DD; Kazanjian PH; Cinti SK; Kauffman CA; Carver PL
    Pharmacotherapy; 2004 Nov; 24(11):1539-45. PubMed ID: 15537559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
    Vella S; Floridia M; Dally LG; Tomino C; Fragola V; Weimer LE; Milazzo F; Mazzotta F; Moroni M; Pastore G; Scalise G; Sinicco A; Ortona L; De Rienzo B; Dianzani F
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):462-9. PubMed ID: 8757422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and gamma scintigraphy evaluation of two enteric coated formulations of didanosine in healthy volunteers.
    Damle B; Ullah I; Doll W; Wiley G; Knupp C
    Br J Clin Pharmacol; 2002 Sep; 54(3):255-61. PubMed ID: 12236845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability of two new formulations of paracetamol, compared with three marketed formulations, in healthy volunteers.
    Sevilla-Tirado FJ; González-Vallejo EB; Leary AC; Breedt HJ; Hyde VJ; Fernández-Hernando N
    Methods Find Exp Clin Pharmacol; 2003 Sep; 25(7):531-5. PubMed ID: 14571283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ; Squires K; Pan-Zhou XR; Bernhard S; Agrofoglio L; Kirk M; Duchin KL; Sommadossi JP
    J Clin Pharmacol; 1997 Mar; 37(3):201-13. PubMed ID: 9089422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).
    Molina JM; Peytavin G; Perusat S; Lascoux-Combes C; Sereni D; Rozenbaum W; Chene G
    HIV Med; 2004 Mar; 5(2):99-104. PubMed ID: 15012649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.
    Hirt D; Bardin C; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Urien S; Foulongne V; Van De Perre P; Tréluyer JM; Msellati P
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4399-406. PubMed ID: 19581461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.